Gemcitabine and sunitinib have been shown to induce apoptosis in tumor cells as well as endothelial cells [49], [50], [51], [52], whereas bevacizumab and EMAP mainly have proapoptotic activity towards endothelial cells [28], [53]. The gene discussed is EML1; the disease is neoplasm.